BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 38423595)

  • 1. Impact of Tumor Grade Distribution on Genetic Alterations in Clear Cell Renal Cell Carcinoma and Prostate Cancer.
    Mizutani K; Sugiyama S; Kameyama K; Kamei S; Yokoi S; Morikawa A; Takeuchi M; Seike K; Yamada T; Ehara H; Sawada S; Hirade K; Furuta H; Matsunaga K; Yamada T; Sakamoto I; Kato Y; Nishihara H; Ishihara S; Deguchi T
    Cancer Genomics Proteomics; 2024; 21(2):203-212. PubMed ID: 38423595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutational heterogeneity between different regional tumour grades of clear cell renal cell carcinoma.
    Ferronika P; Kats-Ugurlu G; Haryana SM; Utoro T; Rinonce HT; Danarto R; de Lange K; Terpstra MM; Sijmons RH; Westers H; Kok K
    Exp Mol Pathol; 2020 Aug; 115():104431. PubMed ID: 32259515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive genomic profiling of metastatic collecting duct carcinoma, renal medullary carcinoma, and clear cell renal cell carcinoma.
    Bratslavsky G; Gleicher S; Jacob JM; Sanford TH; Shapiro O; Bourboulia D; Gay LM; Andrea Elvin J; Vergilio JA; Suh J; Ramkissoon S; Severson EA; Killian JK; Schrock AB; Chung JH; Miller VA; Mollapour M; Ross JS
    Urol Oncol; 2021 Jun; 39(6):367.e1-367.e5. PubMed ID: 33775530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma.
    Hakimi AA; Chen YB; Wren J; Gonen M; Abdel-Wahab O; Heguy A; Liu H; Takeda S; Tickoo SK; Reuter VE; Voss MH; Motzer RJ; Coleman JA; Cheng EH; Russo P; Hsieh JJ
    Eur Urol; 2013 May; 63(5):848-54. PubMed ID: 23036577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA damage response alterations in clear cell renal cell carcinoma: clinical, molecular, and prognostic implications.
    Jing X; Qin X; Liu H; Liu H; Wang H; Qin J; Zhang Y; Cao S; Fan X
    Eur J Med Res; 2024 Feb; 29(1):107. PubMed ID: 38326910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular characteristics and markers of advanced clear cell renal cell carcinoma: Pitfalls due to intratumoral heterogeneity and identification of genetic alterations associated with metastasis.
    Obeng RC; Arnold RS; Ogan K; Master VA; Pattaras JG; Petros JA; Osunkoya AO
    Int J Urol; 2020 Sep; 27(9):790-797. PubMed ID: 32638444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clear Cell Type A and B Molecular Subtypes in Metastatic Clear Cell Renal Cell Carcinoma: Tumor Heterogeneity and Aggressiveness.
    Serie DJ; Joseph RW; Cheville JC; Ho TH; Parasramka M; Hilton T; Thompson RH; Leibovich BC; Parker AS; Eckel-Passow JE
    Eur Urol; 2017 Jun; 71(6):979-985. PubMed ID: 27899233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unique characteristics of tertiary lymphoid structures in kidney clear cell carcinoma: prognostic outcome and comparison with bladder cancer.
    Masuda T; Tanaka N; Takamatsu K; Hakozaki K; Takahashi R; Anno T; Kufukihara R; Shojo K; Mikami S; Shinojima T; Kakimi K; Tsunoda T; Aimono E; Nishihara H; Mizuno R; Oya M
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35314433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genomic Alterations of Renal Cell Carcinoma and Clinical Implications in the Chinese Population.
    Zhang S; Wang B; Zhang F; Ye J; Ge L; Ma L
    Med Sci Monit; 2019 Apr; 25():2959-2965. PubMed ID: 31007253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Novel Tumor Mutation Burden Related lncRNA Signature Identified Prognosis and Tumor Immune Microenvironment Features in Clear Cell Renal Cell Carcinoma.
    Lin L; Wu XH; Zhu JM; Chen SH; Chen YH; Lin F; Xue XY; Wei Y; Xu N; Zheng QS; Sun XL
    Comb Chem High Throughput Screen; 2023; 26(8):1503-1518. PubMed ID: 36165528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tracing Clonal Dynamics Reveals that Two- and Three-dimensional Patient-derived Cell Models Capture Tumor Heterogeneity of Clear Cell Renal Cell Carcinoma.
    Bolck HA; Corrò C; Kahraman A; von Teichman A; Toussaint NC; Kuipers J; Chiovaro F; Koelzer VH; Pauli C; Moritz W; Bode PK; Rechsteiner M; Beerenwinkel N; Schraml P; Moch H
    Eur Urol Focus; 2021 Jan; 7(1):152-162. PubMed ID: 31266731
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of long non-coding RNA transcriptome in clear-cell renal cell carcinoma by next-generation deep sequencing.
    Malouf GG; Zhang J; Yuan Y; Compérat E; Rouprêt M; Cussenot O; Chen Y; Thompson EJ; Tannir NM; Weinstein JN; Valero V; Khayat D; Spano JP; Su X
    Mol Oncol; 2015 Jan; 9(1):32-43. PubMed ID: 25126716
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clear cell renal cell carcinoma with prominent microvascular hyperplasia: Morphologic, immunohistochemical and molecular-genetic analysis of 7 sporadic cases.
    Alaghehbandan R; Limani R; Ali L; Rogala J; Vanecek T; Steiner P; Hajkova V; Kuthi L; Slisarenko M; Michalova K; Pivovarcikova K; Hora M; Pitra T; Michal M; Hes O
    Ann Diagn Pathol; 2022 Feb; 56():151871. PubMed ID: 34847388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deciphering intratumor heterogeneity in clear cell renal cell carcinoma utilizing clinicopathologic and molecular platforms.
    Vormittag-Nocito E; Mannan R; Wang X; Chinnaiyan A; Zhang Y; Zelenka-Wang S; Cao X; Morgan TM; Hafez K; Vaishampayan U; Abdulfatah E; Chinnaiyan AM; Dhanasekaran SM; Mehra R
    Hum Pathol; 2022 Dec; 130():95-109. PubMed ID: 36511267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study.
    Voss MH; Reising A; Cheng Y; Patel P; Marker M; Kuo F; Chan TA; Choueiri TK; Hsieh JJ; Hakimi AA; Motzer RJ
    Lancet Oncol; 2018 Dec; 19(12):1688-1698. PubMed ID: 30416077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Heredity in renal and prostatic neoplasia].
    Prayer Galetti T; D'Arrigo L; De Zorzi L; Patarnello T
    Arch Ital Urol Androl; 1997 Sep; 69(4):241-6. PubMed ID: 9417296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification and validation of novel prognostic markers in Renal Cell Carcinoma.
    Rabjerg M
    Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor grade estımatıon of clear cell and papıllary renal cell carcınomas usıng contrast-enhanced MDCT and FSE T2 weıghted MR ımagıng: radıology-pathology correlatıon.
    Halefoglu AM; Ozagari AA
    Radiol Med; 2021 Sep; 126(9):1139-1148. PubMed ID: 34100169
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Landscape of Whole-genome Alterations and Pathologic Features in Genitourinary Malignancies: An Analysis of the Cancer Genome Atlas.
    Ball MW; Gorin MA; Drake CG; Hammers HJ; Allaf ME
    Eur Urol Focus; 2017 Dec; 3(6):584-589. PubMed ID: 28753846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization and Impact of TERT Promoter Region Mutations on Clinical Outcome in Renal Cell Carcinoma.
    Casuscelli J; Becerra MF; Manley BJ; Zabor EC; Reznik E; Redzematovic A; Arcila ME; Tennenbaum DM; Ghanaat M; Kashan M; Stief CG; Carlo M; Voss MH; Feldman DR; Motzer RJ; Chen Y; Reuter VE; Coleman JA; Russo P; Hsieh JJ; Hakimi AA
    Eur Urol Focus; 2019 Jul; 5(4):642-649. PubMed ID: 28951115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.